EquityGroups

Pharma Equity Group is a Danish biopharmaceutical company that operates primarily through its subsidiary, Reponex Pharmaceuticals. The company specializes in a drug repositioning strategy, which involves identifying new therapeutic uses for established active substances, particularly through local administration to target diseases more precisely and reduce systemic toxicity. Its clinical pipeline is centered on the use of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and other repositioned agents to treat serious conditions such as peritonitis, chronic non-healing wounds, and inflammatory bowel diseases. Pharma Equity Group is listed on the Nasdaq Copenhagen exchange and operates with a capital-light business model aimed at out-licensing its programs following the completion of Phase II clinical trials.